Benzinga · Nov 2, 2026
MaxCyte 13D Filing Shows Liontrust Investment Partners Reports 4.9% Stake In The Co As Of October 30, 2026
- SEC Filing
MX
NASDAQ · MXCT
MaxCyte, Inc.
Healthcare · Medical - Devices
$1.13
Down-$0.17 (-13.08%)
Updated Nov 11, 2026, 2:36 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 170.68M
- P/E ratio
- -3.73
- Dividend yield
- 0.00%
- 52-week range
- $0.64 – $1.81
- Volume
- 4.48M
- Avg. volume
- 961.6K
Price performance · MXCT
MXCT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 10, 2026
MXCT closed at $1.13 after 21 trading sessions, up 17.18% for the selected period.
- Last close
- $1.13
- Period change
- +17.18%
- Period low
- $0.96
- Period high
- $1.73
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 10, 2026 | $1.40 | $1.42 | $1.08 | $1.13 | 4.48M |
| Nov 9, 2026 | $1.25 | $1.35 | $1.25 | $1.30 | 1.6M |
| Nov 6, 2026 | $1.31 | $1.36 | $1.24 | $1.26 | 876.55K |
| Nov 5, 2026 | $1.39 | $1.421 | $1.29 | $1.31 | 873.65K |
| Nov 4, 2026 | $1.47 | $1.48 | $1.36 | $1.39 | 855.97K |
| Nov 3, 2026 | $1.51 | $1.51 | $1.365 | $1.46 | 1.03M |
| Nov 2, 2026 | $1.59 | $1.705 | $1.43 | $1.45 | 1.28M |
| Oct 30, 2026 | $1.71 | $1.72 | $1.505 | $1.59 | 963.82K |
| Oct 29, 2026 | $1.73 | $1.76 | $1.6229 | $1.73 | 1.14M |
| Oct 28, 2026 | $1.50 | $1.73 | $1.50 | $1.71 | 1.71M |
| Oct 27, 2026 | $1.51 | $1.64 | $1.51 | $1.54 | 1.58M |
| Oct 26, 2026 | $1.39 | $1.53 | $1.3649 | $1.51 | 1.13M |
| Oct 23, 2026 | $1.43 | $1.43 | $1.35 | $1.40 | 757.46K |
| Oct 22, 2026 | $1.44 | $1.51 | $1.43 | $1.43 | 1.02M |
| Oct 21, 2026 | $1.42 | $1.53 | $1.405 | $1.47 | 1.42M |
| Oct 20, 2026 | $1.29 | $1.4567 | $1.29 | $1.43 | 1.39M |
| Oct 19, 2026 | $1.30 | $1.31 | $1.27 | $1.30 | 986.46K |
| Oct 16, 2026 | $1.32 | $1.32 | $1.28 | $1.30 | 1.01M |
| Oct 15, 2026 | $1.27 | $1.31 | $1.255 | $1.30 | 3.79M |
| Oct 14, 2026 | $1.225 | $1.33 | $1.195 | $1.25 | 12.67M |
| Oct 13, 2026 | $0.9813 | $1.01 | $0.9361 | $0.9643 | 327.91K |
Latest MXCT news
The latest Smart Investors Daily articles mentioning MXCT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
MXCT research
Overview
Company profile and research snapshot.
Company profile
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 25, 2026 | Craig-Hallum | Buy | — |
| Aug 11, 2025 | BTIG | Neutral | — |
| Aug 7, 2025 | William Blair | Market Perform | — |
| Mar 12, 2025 | Stifel | Buy | — |
| Apr 23, 2024 | Stephens & Co. | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 28, 2026
MaxCyte to Participate in Three Upcoming Investor Conferences
ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced Company management will participate in three upcoming investor conferences. Stifel 2026 Healthcare ConferenceFireside Chat on Wednesday, November 11th at 4:40 PM ET17th Annual Craig-Hallum Alpha Select ConferenceTuesday, November
ChartMill · Oct 15, 2026
These stocks have an unusual volume in today's session
On Thursday, there are stocks with unusual volume. Let's take a look.
Benzinga · Oct 15, 2026
MaxCyte 13D Filing Shows Liontrust Investment Partners Reports 5% Stake In Co. As Of Oct. 14
https://www.sec.gov/Archives/edgar/data/1287098/000154420426000009/xslSCHEDULE_13D_X02/primary_doc.xml
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
